Morning Kick Supplement by Roundhouse Provisions: 2026 Consumer Guide Examines Ingredients, Suitability, and What to Realistically Expect Third-Party Educational Resource Provides Formulation Breakdown, Contraindication Guidance, and Research-Informed Expectations for Roundhouse Provisions Morning Kick GlobeNewswire January 07, 2026 HOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does […]

(NasdaqGM:SORNU),(NasdaqGM:SORN),(NasdaqGM:SORNW), Miami, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) — Soren Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, January 7, 2026, under

Soren Acquisition Corp. Announces the Pricing of $220,000,000 Initial Public Offering GlobeNewswire January 07, 2026 Miami, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) — Soren Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on

(NASDAQ:CRNX), SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire January 07, 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public

Best RFID Blocking Card: Consumer Verification Analysis Examines Wallet Defender Signal-Blocking Technology as January Search Volume Reaches Post-Holiday Peak Publication addresses verification gap for consumers conducting post-advertisement due diligence on RFID protection products; analysis examines Wallet Defender passive electromagnetic interference technology, business legitimacy framework, and Self-Assessment criteria as contactless card security searches increase across major

(NYSE:KLAR), SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Klarna Group plc (NYSE: KLAR) securities pursuant and/or traceable to Klarna's offering documents issued in connection with Klarna's September 10, 2025 initial public offering (the “IPO”), have until February 20,

KLAR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Klarna Group plc Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire January 07, 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Klarna Group

HOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility. If you purchase through links in this article, a commission may be earned at

Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform Structure GlobeNewswire January 07, 2026 HOUSTON, TX, Jan. 06, 2026 (GLOBE